BioN­Tech, Au­to­lus strike wide-rang­ing li­cens­ing and man­u­fac­tur­ing deal for CAR-T ther­a­pies

BioN­Tech is en­list­ing CAR-T biotech Au­to­lus Ther­a­peu­tics on a part­ner­ship aimed at push­ing both of their CAR-T pro­grams to­ward com­mer­cial­iza­tion, with an eye on its new part­ner’s pro­grams as well as man­u­fac­tur­ing ca­pa­bil­i­ties.

As part of the wide-rang­ing agree­ment, BioN­Tech will pur­chase $200 mil­lion of Au­to­lus’ shares in a pri­vate place­ment, plus dish out a cash pay­ment of $50 mil­lion.

In ex­change, BioN­Tech will re­ceive up to mid-sin­gle dig­it roy­al­ty on net sales of Au­to­lus’ lead CD19 ther­a­py, obe-cel, which is now un­der re­view at the FDA for re­lapsed/re­frac­to­ry adult B cell acute lym­phoblas­tic leukemia. It will al­so have an op­tion to get a prof­it share on Au­to­lus’ oth­er CAR-T ther­a­pies, AU­TO1/22 and AU­TO6NG, in any can­cer type, if it co-sup­ports de­vel­op­ment and com­mer­cial­iza­tion. Au­to­lus will be el­i­gi­ble to re­ceive an op­tion ex­er­cise fee, mile­stone pay­ments and co-fund­ing of de­vel­op­ment ex­pens­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER